Comment on The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.

The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.

Tirzepatide, a once-weekly injection to treat diabetes and obesity, is no longer in shortage, the FDA announced, potentially signaling a crackdown on copycat drugs in early 2025.MarsBars/Getty ImagesTirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says.Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025.Patients could face higher costs and tougher access, and telehealth is racing to adapt.The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025.Tirzepatide is the active ingredient in Eli Lilly's drugs Mounjaro and Zepbound, branded to treat diabetes and obesity, respectively.They're part of a class of medications called GLP-1 agonists, including semaglutide (sold as Ozempic and Wegovy), which have transformed obesity treatment in recent years.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News